Andreas Grüneisen

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

Thomas Büchner, Wolfgang E. Berdel, Claudia Haferlach et al. · Journal of Clinical Oncology · 2008 · 337 citations

Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies

Torsten Haferlach, Claudia Schoch, Helmut Löffler et al. · Journal of Clinical Oncology · 2003 · 188 citations

6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group

Thomas Büchner, Wolfgang Hiddemann, Wolfgang E. Berdel et al. · Journal of Clinical Oncology · 2003 · 163 citations

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

Eva Lengfelder, Claudia Haferlach, Torsten Haferlach et al. · Leukemia · 2009 · 133 citations

Hematological Malignancy, High Dose Ara-c, Mixed-phenotype Acute Leukemia +7

Drug induced immune haemolytic anaemia in the Berlin Case‐Control Surveillance Study

Edeltraut Garbe, Frank Andersohn, Elisabeth Bronder et al. · British Journal of Haematology · 2011 · 98 citations · Full text